Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(5):407-408; doi:10.1093/jnci/91.5.407
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Moulton, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moulton, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 5, 407-408, March 3, 1999
© 1999 Oxford University Press

NEWS

Panel Finds In Utero Gene Therapy Proposal Is Premature

Gwen Moulton

How can consent be informed when the "patient" is a fetus? Is it appropriate to begin clinical trials involving prenatal gene therapy when the potential risks to the mother, the fetus, and the child's possible offspring are not fully understood? And how would such trials be designed?

These and other ethical questions are being deliberated as a result of the recent proposal to the National Institutes of Health Recombinant DNA Advisory Committee to begin human trials of in utero gene transfer (See News, Oct. 21, 1998.)

For now, working groups at the third NIH Gene Therapy Policy Conference on "Prenatal Gene Transfer: Scientific, Medical and Ethical Issues" have concluded that there is insufficient preclinical data to support starting phase . . . [Full Text of this Article]

" Minimal" Risks

IRB Oversight

Stretching Consent?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?